top of page

Cresemba Milestone Payments Continue to Roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. Edison Group notes that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the first of two Phase III trials expected to initiate in mid-2024. The company also made positive regulatory and operational strides with its lead antibiotic asset, Zevtera (following FDA approval in April 2024), and Edison eagerly await the announcement of a potential US commercial partner.

17 May 2024


f5d4e17b7b243c7acea6015aa9be1567 (1)
.pdf
Download PDF • 259KB


0 views0 comments

Recent Posts

See All

Comments


bottom of page